Gaurav Aggarwal Biography and Net Worth

Director of Sierra Oncology


Gaurav Aggarwal, MD, has served as a Managing Director of Vivo Capital LLC, a healthcare focused investment firm, since October 2016, where he focuses on investments in life sciences companies. Dr. Aggarwal previously served as the Chief Business Officer of Ocera Therapeutics, as Managing Director of Investor Growth Capital, and as a General Partner at Panorama Capital, L.P., a venture capital fund. Earlier in his career, Dr. Aggarwal was an associate with JPMorgan Partners, LLC, a private equity division of JPMorgan Chase & Co. Dr. Aggarwal previously served on the Boards of Directors of Hyperion Therapeutics, Inc. (acquired by Horizon Pharma plc) and Microlin Bio, Inc. and on several privately held biopharmaceutical companies. Dr. Aggarwal received his MD from Columbia University, College of Physicians & Surgeons, and his BS in Agricultural Economics from Cornell University.

What is Gaurav Aggarwal's net worth?

The estimated net worth of Gaurav Aggarwal is at least $1.10 million as of January 15th, 2016. Dr. Aggarwal owns 20,000 shares of Sierra Oncology stock worth more than $1,099,800 as of April 26th. This net worth approximation does not reflect any other investments that Dr. Aggarwal may own. Learn More about Gaurav Aggarwal's net worth.

How do I contact Gaurav Aggarwal?

The corporate mailing address for Dr. Aggarwal and other Sierra Oncology executives is 2150-885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. Sierra Oncology can also be reached via phone at (604) 558-6536 and via email at [email protected]. Learn More on Gaurav Aggarwal's contact information.

Has Gaurav Aggarwal been buying or selling shares of Sierra Oncology?

Gaurav Aggarwal has not been actively trading shares of Sierra Oncology during the last ninety days. Most recently, on Monday, January 31st, Gaurav Aggarwal bought 800,000 shares of Sierra Oncology stock. The stock was acquired at an average cost of $27.00 per share, with a total value of $21,600,000.00. Learn More on Gaurav Aggarwal's trading history.

Who are Sierra Oncology's active insiders?

Sierra Oncology's insider roster includes Gaurav Aggarwal (Director), Craig Collard (Director), Stephen Dilly (CEO), Mary Thomson (General Counsel), and William Turner (Insider). Learn More on Sierra Oncology's active insiders.

Gaurav Aggarwal Insider Trading History at Sierra Oncology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/31/2022Buy800,000$27.00$21,600,000.00View SEC Filing Icon  
See Full Table

Gaurav Aggarwal Buying and Selling Activity at Sierra Oncology

This chart shows Gaurav Aggarwal's buying and selling at Sierra Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sierra Oncology Company Overview

Sierra Oncology logo
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.
Read More

Today's Range

Now: $54.99
Low: $54.99
High: $54.99

50 Day Range

MA: $54.93
Low: $54.73
High: $54.99

2 Week Range

Now: $54.99
Low: $14.91
High: $55.19

Volume

N/A

Average Volume

931,731 shs

Market Capitalization

$1.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.03